Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough
Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its Phase 2 trial of EVX-01 (a personalized cancer vaccine for advanced melanoma) at the ESMO Congress in Berlin globenewswire.com. The October presentation (oral session Oct 17, webinar Oct 22) will cover efficacy, immunogenicity, safety, best overall response, and T‑cell response durability of EVX-01 plus Merck’s KEYTRUDA® globenewswire.com. Earlier one-year interim results showed a 69% overall response rate and tumor reduction in 15 of 16 patients globenewswire.com, highlighting the vaccine’s promise. Evaxion’s